Content about Pemetrexed

October 12, 2012
FDA approves Celgene lung-cancer drug

The Food and Drug Administration has approved an injected drug for lung cancer made by Celgene, the company said Friday.

SUMMIT, N.J. — The Food and Drug Administration has approved an injected drug for lung cancer made by Celgene, the company said Friday.

Celgene announced the approval of Abraxane (paclitaxel) protein-bound particles for injectable suspension, for the first-line treatment of non-small cell lung cancer that has advanced locally or spread to other parts of the body, in combination with carboplatin, for patients who are not candidates for curative surgery or radiation therapy.

June 19, 2012
Pfizer: Phase-3 study of Xalkori met primary endpoint

Pfizer announced the results of its late-stage clinical trial of Xalkori (crizotinib).

NEW YORK — Pfizer announced the results of its late-stage clinical trial of Xalkori (crizotinib).

The drug maker confirmed that its Profile 1007 study met its primary endpoint, demonstrating that the drug significantly improved progression-free survival in previously treated patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer, compared with those treated with pemetrexed or docetaxel. The study also marked the first randomized phase-3 study in ALK-positive advanced NSCLC patients, Pfizer said.

September 27, 2011
Study: Lilly drug keeps common lung cancer under control in elderly patients

A drug made by Eli Lilly prevented the most common form of lung cancer from progressing in elderly patients when added to chemotherapy, according to results of a late-stage clinical trial.

INDIANAPOLIS — A drug made by Eli Lilly prevented the most common form of lung cancer from progressing in elderly patients when added to chemotherapy, according to results of a late-stage clinical trial.

Lilly released results of the 939-patient phase-3 "PARAMOUNT" study, which found that maintenance therapy with the injected drug Alimta (pemetrexed), added to the chemotherapy drug cisplatin, reduced the risk of disease progression in patients ages 70 years and older with advanced nonsquamous no-small cell lung cancer, or NSCLC.

June 6, 2011
Alimta extends progression-free survival among patients in late-stage study

Cancer patients taking a drug made by Eli Lilly extended the amount of time they survived without their disease worsening, according to results of a study announced Sunday.

INDIANAPOLIS — Cancer patients taking a drug made by Eli Lilly extended the amount of time they survived without their disease worsening, according to results of a study announced Sunday.

Lilly said results of the phase-3 “PARAMOUNT” study of the injected drug Alimta (pemetrexed) extended progression-free survival in patients with nonsquamous nonsmall-cell lung cancer. The study focused on continuation maintenance when one of the same drugs used as a first-line treatment for cancer is continued as maintenance therapy in an effort to control the disease.

January 25, 2011
Head of Lilly's oncology biz resigns

John Johnson is bidding Eli Lilly adieu.

INDIANAPOLIS — John Johnson is bidding Eli Lilly adieu.

Johnson, who served as SVP and president of the drug maker's oncology business — whose portfolio includes Alimta (pemetrexed) and Gemzar (gemcitabine hydrochloride) — resigned, effective Jan. 28. Johnson is taking on the chief executive role at specialty biopharmaceutical company Savient, effective Jan. 31. Savient is best known for its chronic gout treatment Krystexxa (pegloticase), which received regulatory approval in September 2010.

November 15, 2010
Generic versions of Alimta, Abilify get shut down by district courts

The U.S. District Court for the District of Delaware has upheld a patent held by...

INDIANAPOLIS — The U.S. District Court for the District of Delaware has upheld a patent held by Indianapolis-based drug maker Eli Lilly covering a chemotherapy drug, Lilly said Monday.

 

The case concerns a patent covering Alimta (pemetrexed) that expires in July 2016 and generic drug maker Teva Pharmaceutical Industries’ challenge to it.

 

 

May 16, 2010
Lilly to present more than 50 studies at oncology conference

The cancer drug arm of Eli Lilly plans to show data from more than 50...

March 17, 2010
Lilly comments on drug theft at Connecticut facility

Drugs stolen from an Eli Lilly warehouse in Connecticut Sunday unlikely are to make it...